Navigation Links
Abide Therapeutics Announces Collaboration With Merck to Develop Novel Therapies for Type 2 Diabetes and Metabolic Diseases
Date:5/2/2013

SAN DIEGO, May 02, 2013 /PRNewswire/ -- Abide Therapeutics, a biopharmaceutical company pioneering innovative approaches to selectively target a group of enzymes known as serine hydrolases, today announced that it has entered into a collaboration agreement with Merck, known as MSD outside the U.S. and Canada, to discover, develop and commercialize small-molecule therapies directed against three novel targets to treat metabolic diseases with a focus on type 2 diabetes.

(Logo: http://photos.prnewswire.com/prnh/20130502/LA06084LOGO)

"This collaboration leverages Abide's unique and innovative therapeutic engine," said Alan Ezekowitz , MBChB, D.Phil., President and CEO of Abide Therapeutics.  "We are eager to validate unique targets that we hope will lead to the development of novel therapeutics that will benefit patients with diabetes and metabolic diseases." 

Under the terms of the agreement, Abide Therapeutics is eligible to receive an upfront payment, research funding, and potential milestone payments for up to $430 million for three products. Further details of the financial terms were not disclosed. Merck will have worldwide commercialization rights to any products that may be developed as a result of the collaboration. Abide Therapeutics is entitled to receive royalty payments on global sales from any such products.

"Diabetes and related disorders continue to represent a significant global, unmet medical need," said Nancy Thornberry , Senior Vice President and Franchise Head, Diabetes and Metabolism, Merck Research Laboratories. "We look forward to working with Abide on the discovery and development of important new medicines."

About Serine Hydrolases

The large family of serine hydrolases
'/>"/>

SOURCE Abide Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Algeta and Lumiphore Announce Further Expansion of Their Global Partnership for the Development of Targeted Alpha-pharmaceutical Cancer Therapeutics and Companion Diagnostics.
2. Combination Drugs are the Future of the European Hepatitis B and C Therapeutics Markets, Says Frost & Sullivan
3. SMaRT Therapeutics Announces Appointment of Dr. John H. Abeles to the Advisory Board
4. Inhibikase Therapeutics to present at 5th International Congress on Polyomaviruses and Human Diseases
5. Immunomic Therapeutics Announces Interim Data Analysis of Phase I Study to Treat Japanese Red Cedar Allergy
6. PTC Therapeutics Appoints Mark Rothera As Chief Commercial Officer
7. DSM and DecImmune Therapeutics Sign Agreement to Develop N2 Pathway Blocking Antibody
8. Serina Therapeutics Announces Agreement Retaining Woodside Capital Partners as Advisor and Investment Bank
9. Serina Therapeutics Announces Worldwide Exclusive License Agreement with The Scripps Research Institute for Click Chemistry
10. Mast Therapeutics Presents MST-188 Data at 7Th Annual Sickle Cell Disease Research and Educational Symposium
11. Society for Brain Mapping and Therapeutics (SBMT) announce the formation of American Board of Brain Mapping, its 2013 award recipients and its Brain Mapping Day at the US Congress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... HAMILTON, N.J. , Oct. 22, 2014 ... CLIA-certified, CAP-accredited laboratory which specializes in high ... that it is now offering new Cystic ... including next- generation DNA sequencing platforms. ... a genetically inherited multisystem disorder that affects ...
(Date:10/22/2014)... , Oct 22, 2014 Antigen Discovery ... Irvine, California , announced the receipt of a ... Innovation Research award (SBIR) from the National Institute of Dental and ... the development of a Pan-HIV Protein Microarray Chip, which ... and HIV-2 subtypes and aid in the development of ...
(Date:10/22/2014)... AVACEN Medical announced today that its AVACEN ... clearance by the U.S. Food and Drug Administration. This ... the Internet for: the temporary relief of joint ... and sprains . Logo - http://photos.prnewswire.com/prnh/20141021/153513 ... is a sophisticated medical device incorporating over 3,000 firmware ...
Breaking Medicine Technology:Medical Diagnostic Laboratories, L.L.C. Institute for Biomarker Research Announces New Prenatal Cystic Fibrosis Tests 2Biomarker Discovery Company, Antigen Discovery Inc., Awarded an NIH Phase I Small Business Innovation Research Grant to Develop a Pan-HIV Protein Microarray Chip 2AVACEN Medical Announces FDA Clearance of First Medical Device with Internal Game Mode 2
... International,Inc. (NYSE: BAX ) announced today that ... IX proteins to treat hemophilia B.,Baxter will develop ... of acute bleeding episodes and a chemically modified, ... of bleeding in,hemophilia B patients. Hemophilia B is ...
... Nanoparticles May Deliver Treatments to Human,Organs -, PHILADELPHIA, ... iron-bearing particles to drive healthy cells to,targeted sites in ... to,a new method of delivering cells and genes to ... http://www.newscom.com/cgi-bin/prnh/20080107/DC10966 ), The study team, led by ...
Cached Medicine Technology:Baxter Announces Recombinant Factor IX Development Program For Hemophilia B 2Baxter Announces Recombinant Factor IX Development Program For Hemophilia B 3Researchers Use Magnetism to Target Cells to Animal Arteries 2Researchers Use Magnetism to Target Cells to Animal Arteries 3Researchers Use Magnetism to Target Cells to Animal Arteries 4
(Date:10/25/2014)... Randy Dotinga HealthDay Reporter ... more genetic tests are developed that spot increased risks for ... more proactive about getting screened. But a new study ... change behavior: People who found out their genes doubled their ... with average risk to get screened. "It didn,t make ...
(Date:10/22/2014)... On Saturday, October 25, 2014, the Brownsville Community ... and fitness fair ¡Vive tu vida! Get Up! Get Moving!®. ... for better health and wellness for people of all ages ... to the public, will be held at Dean Porter Park, ... 1:00 pm. , “¡Vive tu Vida! Get Up! Get ...
(Date:10/22/2014)... 22, 2014 Isabel Healthcare ... Health Professions (ASAHP) Conference on October 22-24 in Las ... participate in a panel discussion on Technology in Health ... Healthcare provides a diagnostic decision support tool and clinical ... skills of students and clinical learners. The Isabel tools ...
(Date:10/22/2014)... (HealthDay News) -- The United States is now ... nations of West Africa land at one of ... with the virus. In a statement released ... 94 percent of air passengers from Guinea, Liberia ... these five airports -- New York City,s Kennedy ...
(Date:10/22/2014)... 2014 Hay House is pleased to announce ... Upgrade Your Life (Paperback; $10.82) written by the highly esteemed ... This book is meant to help readers of all ... recovery. , Recovery 2.0 is not the average self-help ... is a guide for what comes next. For ...
Breaking Medicine News(10 mins):Health News:Knowing Genetic Risk for Cancer May Not Change Behavior 2Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 2Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 3Health News:Brownsville Community Health Center Presents Fourth Annual ¡Vive Tu Vida! Get Up! Get Moving!® Event 4Health News:Isabel Healthcare to Participate in The Association of Schools of Allied Health Professions (ASAHP) 2014 Conference 2Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 2Health News:Passengers From Ebola-Affected Countries Must Land at Designated U.S. Airports 3Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 2Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 3
... -- Winner Medical Group Inc.,(OTC Bulletin Board: WMDG) (,Winner Medical, ... quarter ended December 31,2008. The Company,s results are detailed in ... Exchange Commission. , , First Quarter 2009 ... by 33.14% over the first quarter of, ...
... development, today announces that it has appointed Riccardo Nisato, MBA, PhD, ... CH. Dr. Nisato will be responsible for replicating Stemedica,s U.S. ... , ... San Diego, Calif. (PRWEB) February 13, 2009 -- ...
... Feb. 12 The Ensign Group, Inc. (Nasdaq: ... the Ensign(TM) group of skilled nursing, rehabilitative care ... it expects to issue its fourth quarter and ... close on Wednesday, February 18, 2009.(Logo: ...
... and Valentine,s Day LOS ANGELES, Feb. 12 Don,t ... In celebration of National Condom Week, Planned Parenthood Los ... application on Facebook to help remind everyone -- and ... against sexually transmitted diseases (STDs) and unplanned pregnancy. " ...
... , , THURSDAY, Feb. 12 (HealthDay News) -- People exposed ... 44 percent increased risk of developing dementia, a new ... connection between smoking and increased risk for dementia and ... to date showing a link between secondhand smoke and ...
... legislation intended to help reduce cardiovascular disease in ... that could force some women to make tough ... Lisa Murkowski (R-AK) and Congresswomen Lois Capps (D-CA) ... that would expand access to screening and lifestyle ...
Cached Medicine News:Health News:Winner Medical Reports First Quarter Fiscal 2009 Results 2Health News:Winner Medical Reports First Quarter Fiscal 2009 Results 3Health News:Winner Medical Reports First Quarter Fiscal 2009 Results 4Health News:Winner Medical Reports First Quarter Fiscal 2009 Results 5Health News:Winner Medical Reports First Quarter Fiscal 2009 Results 6Health News:Winner Medical Reports First Quarter Fiscal 2009 Results 7Health News:Winner Medical Reports First Quarter Fiscal 2009 Results 8Health News:Winner Medical Reports First Quarter Fiscal 2009 Results 9Health News:Winner Medical Reports First Quarter Fiscal 2009 Results 10Health News:Stemedica Announces the Appointment of Riccardo Nisato, MBA, PhD as Director of Manufacturing and Clinical Business Development for Stemedica International 2Health News:Stemedica Announces the Appointment of Riccardo Nisato, MBA, PhD as Director of Manufacturing and Clinical Business Development for Stemedica International 3Health News:The Ensign Group Schedules 2008 Year End Earnings Call for Thursday, February 19, 2009 2Health News:Planned Parenthood Offers E-Condoms on Facebook 2Health News:Secondhand Smoke Linked to Dementia 2Health News:Stabenow, Murkowski, Capps and Bono Mack Reintroduce HEART for Women Act 2Health News:Stabenow, Murkowski, Capps and Bono Mack Reintroduce HEART for Women Act 3Health News:Stabenow, Murkowski, Capps and Bono Mack Reintroduce HEART for Women Act 4
... sunwear, inspired by modern American ... with long lasting wearability. The ... include sophistication, elegance and enduring ... modern shapes, classic styling and ...
... mounting technology has redefined rimless collections forever.,The ... at the end of each frame mounting. ... the bushing that mounts within the lens. ... secure fit is created that far exceeds ...
... collection celebrates the 85th anniversary of the ... feel, the unmistakable icons that made GUCCI ... and sunglass collection, dedicated to a multifaceted ... design that is the hallmark of the ...
... Whisper NG Erbium YAG Extended Ablation laser ... true laser peel with outstanding results and no ... a proprietary fluence level with an extra long ... skin. Peeling is spread over 3-5 days, ...
Medicine Products: